Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control

Atherosclerosis

Volumn 166, Issue 1, 2003, Pages 151-161

  Cavallero, Elisabeth ^d   Dachet, Christiane ^a   Assadolahi, Farideh ^a   Martin, Claude ^a   Navarro, Nicole ^a   Ansquer, Jean Claude ^b   Corda, Christophe ^b   Foucher, Christelle ^b   Juhan Vague, Irene ^c   Jacotot, Bernard ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b Laboratoires Fournier SA   (France)

^c TIMONE HOSPITAL   (France)

^d NONE

Author keywords

Fibrinogen; Lipase activities; Micronized fenofibrate; Postprandial lipemia; Type 2 diabetes mellitus

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; FENOFIBRATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; METFORMIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RETINOL PALMITATE; SULFONYLUREA; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; BIGUANIDE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY FAT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; ENZYME ACTIVITY; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LUNG FUNCTION TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; BLOOD; COMPARATIVE STUDY; FAT INTAKE; HYPERLIPIDEMIA; MIDDLE AGED; POSTPRANDIAL STATE; TREATMENT OUTCOME;

ADULT; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; BIGUANIDES; CHOLESTEROL, VLDL; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DOUBLE-BLIND METHOD; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PROCETOFEN; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0037211980     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00321-0     Document Type: Article

References (35)

1. Laakso M., Lehto S., Penttilä I., Pyörälä K. Lipids and lipoproteins predicting coronary artery disease mortality and morbidity in patients with non-insulin dependent diabetes. Circulation. 88:1993;1421-1430.
2. Pyörälä K., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab. Rev. 3:1987;463-524.
3. De Man F.H., Cabezas M.C., Van Barlinger H.H., Erkelens D.W., de Bruin T.W. Triglyceride-rich lipoproteins in non-insulin dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur. J. Clin. Invest. 26:1996;89-108.
4. Fontbonne A., Eschwege E., Cambien F., et al. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia. 32:1989;300-304.
5. Taskinen M.R. Diabetic dyslipidemia in NIDDM. Int. Diabetes Monit. 8:1996;1-7.
6. Cavallero E, Neufcour D, Dachet C, Jacotot B. Basal and postprandial evaluation of post-heparin lipolytic activities and lipoprotein composition in diabetic patients. In: Proceedings of the Eighth International Symposium on Atherosclerosis, Rome, October 1988, p. 134.
7. Cavallero E, Jacotot B. Study of fasting and postprandial lipoproteins in NIDDM. In: Stein O, Eisenberg S, Stein Y editors. Atherosclerosis IX R&L Commun. 1992, pp. 479-83.
8. Lewis G.F., O'Meara N.M., Soltys P.A., et al. Fasting hypertriglyceridemia in non-insulin dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J. Clin. Endocrinol. Metab. 72:1991;934-944.
9. Patsch J.R., Meisenbock G., Hopferweiser T., et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler. Thromb. 12:1992;1336-1345.
10. Simpson H.S., Williamson C.M., Olivecrona T., et al. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis. 85:1990;193-202.
11. Roche H.M., Gibney M.J. The impact of postprandial lipemia in accelerating atherothrombosis. J. Cardiovasc. Risk. 7:2000;317-324.
12. Patsch W., Esterbauer H., Foger B., Patsch J.R. Postprandial lipemia and coronary risk. Curr. Atheroscler. Rep. 2:2000;232-242.
13. Heller F., Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate, and probucol on plasma lipolytic enzymes in normolipidaemic subjects. Eur. J. Clin. Pharmacol. 23:1983;57-63.
14. Staels B., Vu-Dac N., Kosykh V.A., Saladin R., Fruchart J.C., Dallongeville J., Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 95:1995;705-712.
15. Martin G., Schoonjans K., Lefebvre A.M., Staels B., Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J. Biol. Chem. 272:1997;28210-28217.
16. Syvänne M., Vuorinen-Markkola H., Hilden H., Taskinen M.R. Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes. Arterioscler. Thromb. 13:1993;286-295.
17. Attia N., Durlach V., Roche D., et al. Post-prandial metabolism of triglyceride-rich lipoproteins in non-insulin-dependent diabetic patients before and after bezafibrate treatment. Eur. J. Clin. Invest. 27:1997;55-63.
18. Sheu W. H.H., Jeng C.Y., Lee W.J., Lin S.Y., Chen Y.T. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia. Metabolism. 50:2001;355-359.
19. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
20. Bouthillier D., Sing D.F., Davignon J. Apolipoprotein phenotyping with a single gel method: application to the study of informative mating. J. Lipid Res. 24:1983;1060-1069.
21. Beaumont J.L., Assadollahi F. Retinyl palmitate labelled intestinally derived lipoproteins accumulate in the circulation of WHHL rabbits. Atherosclerosis. 85:1990;103-111.
22. Cavallero E., Dachet C., Neufcour D., Wirquin E., Mathe D., Jacotot B. Postprandial amplification of lipoprotein abnormalities in controlled type 2 diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels. Metabolism. 43:1994;270-278.
23. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
24. Dachet C., Cavallero E., Martin C., Girardot G., Jacotot B. Effect of gemfibrozil on the concentration and composition of very low and low density lipoprotein subfractions in hypertriglyceridemic patients. Atherosclerosis. 113:1995;1-9.
25. Scelles V., Raccah D., Alessi M.C., Vialle J.M., Juhan-Vague I., Vague P. Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states. Diabetes Metab. 18:1992;38-42.
26. Reznik Y., Pousse P., Herrou M., et al. Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin dependent diabetic patients: influence of apolipoprotein E polymorphism. Metabolism. 45:1996;63-71.
27. Cohn J.S., Johnson E.J., Millar J.S., et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J. Lipid Res. 34:1993;2033-2040.
28. Lindén D., Lindberg K., Oscarsson J., et al. Influence of peroxisome proliferator-activated receptor α agonists on the intracellular turnover and secretion of apolipoprotein (apo) B-100 and ApoB-48. J. Biol. Chem. 277:2002;23044-23053.
29. Shepherd J., Griffin B., Caslake M., Gaw A., Packard C. The influence of fibrates on lipoprotein metabolism. Gotto A.M. Jr, Paoletti R. Atherosclerosis review. 22:1991;163-169 Raven Press, New York.
30. Föger B., Drexel H., Hopferwieser T., et al. Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia. Clin. Invest. 72:1994;294-301.
31. Weintraub M.S., Eisenberg S., Breslow J. Different patterns of postprandial lipoprotein metabolism in normal, Type IIa, Type IV, and Type V hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil. J. Clin. Invest. 79:1987;1110-1119.
32. Frost R.J.A., Otto C., Geiss H.C., Schwandt P., Parhofer K.G. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am. J. Cardiol. 87:2001;44-48.
33. Jeppesen J., Zhou M.Y., Chen Y.D., Reaven G.M. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care. 17:1994;1093-1099.
34. Tan C.E., Chew L.S., Tai E.S., et al. Benefits of micronized fenofibrate in type 2 diabetes mellitus subjects with good glycemic controls. Atherosclerosis. 154:2001;469-474.
35. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet. 357:2001;905-910.